OSI reports OSI-774 data

Researchers presented data from the first 12 evaluable patients in a 48-patient open-label Phase II study of OSIP 's oral small molecule inhibitor of the epidermal growth factor receptor ( EGFR) to treat refractory non-small cell lung cancer. There were 4 partial responses and 4 cases of stable disease. The primary end point of the study, which enrolled patients with EGFR-positive tumors who had failed platinum chemotherapy, is response rate. Secondary end points include stable disease and time to progression. Side effects included diarrhea and rash. ...